about
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsOpen-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects.Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fieldsEvaluation of chinese-herbal-medicine-induced herb-drug interactions: focusing on organic anion transporter 1.Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters.Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersPharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats.The drug transporter-metabolism alliance: uncovering and defining the interplay.The role of transporters in the pharmacokinetics of orally administered drugs.Role of membrane transporters in the safety profile of drugs.Clearance (née Rowland) concepts: a downdate and an update.The Øie-Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior.Prediction of volume of distribution at steady state in humans: comparison of different approaches.Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.The pharmacology of novel oral anticoagulants.Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK-357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation.Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.Transporter-mediated Alterations in Patients with NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate.Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation.Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.Prediction of drug distribution in rat and humans using an artificial neural networks ensemble and a PBPK model.Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.Mechanisms and the clinical relevance of complex drug-drug interactions
P2860
Q30571118-D7476B20-EC8B-43FC-8CDB-C224184DA1B7Q30614811-C5261DD1-B3FF-4C28-A6CE-41FD5E5E3A60Q33763177-189D6C85-61E7-45C3-8757-1C41BA609A0EQ34597891-990E12BE-647D-4E6A-859F-264DF3B87F2DQ34646772-A54DA26F-9310-403E-ABCB-7726308F6DE5Q34754007-7BAFF191-1C7F-488A-BC82-7039E62A7EAEQ36228911-928DBBD9-6E88-4625-9352-8E07BD6E6EDDQ36539774-B10C69D6-FEDF-4E88-AC59-C2DC85F8D9F0Q36620076-5D50B13C-CC8C-409C-A5F2-9A6AECBA77E9Q36689589-DFC633CA-5384-4948-BFC2-081E62EE456EQ36881996-B1218557-D0A6-4405-B965-6AA4879B88CDQ37485904-708770EF-DB0F-4274-8ECF-6955F5B63BF9Q37537018-13FBCD77-FFE0-4E6F-8DC0-B37FF94F7BC6Q37575644-4279EFFC-696B-4DAA-9173-E51EA5AEFA17Q37813042-354D6CB5-002C-426E-A98A-68F8DB32457BQ37932558-BBA3C501-E4C7-4A8E-B976-A9C67AD33727Q38010485-B92B5C75-DEBE-40B7-BF27-8C5853922BEEQ38017309-2C643B73-260C-4329-881F-01AAA2C91170Q38122099-C6722ADD-B91C-43B4-A6A3-10582522B2FFQ38931285-D26096C0-FAFD-4072-9DC3-58D5BCDDD1DEQ40198351-245A50B0-3A31-4563-888A-87FD4EAD4D19Q41968777-57D45B94-E908-4253-8951-D9290CF59257Q42596957-ECA71BC4-B06F-4624-BF58-8B3F45861DB8Q47260944-824BCEB7-6AD1-4137-8A12-3D944BA86B1CQ47921557-DB563C7D-C5E2-4A5B-90F2-E754FF69A0F1Q50912223-AE270A96-D39E-4422-91AB-78AD338E0609Q51083254-6A49E55F-49E9-4134-B713-9569FD5C8E31Q51298427-7470989D-A6C6-4241-8A9F-748113236BFBQ53301415-7FD45461-49C3-440D-8227-A32AD6A9CFBBQ57490721-700E60D5-364D-4B94-93AA-951B2FC395C1
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of drug transporters on volume of distribution.
@en
Effects of drug transporters on volume of distribution.
@nl
type
label
Effects of drug transporters on volume of distribution.
@en
Effects of drug transporters on volume of distribution.
@nl
prefLabel
Effects of drug transporters on volume of distribution.
@en
Effects of drug transporters on volume of distribution.
@nl
P2860
P1433
P1476
Effects of drug transporters on volume of distribution.
@en
P2093
Anita Grover
Leslie Z Benet
P2860
P2888
P304
P356
10.1208/S12248-009-9102-7
P407
P577
2009-04-28T00:00:00Z
P5875
P6179
1035300589